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Background: There are many molecular differences between estrogen receptor α (ERα)-positive and ER-negative
breast cancers. Recent analyses have shown that the former can be divided into two subtypes, luminal A and
luminal B. These differ in response to endocrine therapy and chemotherapy, and in prognosis. In a previous study,
we found that microRNA (miR)-1290 that was significantly down-regulated in luminal A tumors and its potential
target arylamine N-acetyltransferase 1 (NAT1). The aim of the present study was to determine whether NAT1 is a bona
fide target of miR-1290, and to investigate the impact of NAT1 on breast cancer prognosis.
Methods: Luciferase reporter assays were employed to validate NAT1 as a putative miR-1290 target gene. Expression of
NAT1, ERα, progesterone receptor (PgR) and HER2 was analyzed in 394 breast cancer samples by immunohistochemistry.
Results: NAT1 was confirmed to be a direct target of miR-1290. Levels of expression of NAT1 were positively correlated
with those of ERα (P < 0.0001) and PgR (P < 0.0001), but negatively correlated with both tumor grade and size (P < 0.0001).
Kaplan-Meier analysis showed that the presence of NAT1 was significantly associated with increased overall survival (OS)
(P = 0.0416) in these patients. Similarly, significant associations of NAT1 with disease-free survival (DFS) (P = 0.0048) and OS
(P = 0.0055) in those patients who received adjuvant endocrine therapy with tamoxifen (n = 176) were found. Moreover,
NAT1 was also significantly associated with increased DFS (P = 0.0025) and OS (P = 0.0007) in the subset of lymph
node-positive patients (n = 147). Univariate and multivariate analyses showed significant associations between
levels of NAT1 and DFS (P = 0.0005 and 0.019, respectively).
Conclusions: We report that miR-1290 directly targets the NAT1 3′-UTR and that NAT1 protein expression is correlated
with improved OS of breast cancer patients. NAT1 is a possible prognostic biomarker for lymph node-positive breast
cancer. Thus, miR-1290 and its target NAT1 are associated with important characteristics of breast cancer.
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Breast cancers represent a heterogeneous group of tumors
that are diverse in behavior, outcome, and sensitivity to
therapy. Emerging data demonstrate that stratification of
tumors by gene expression profiles can divide breast cancer
into five main subtypes which are associated with dif-
ferent clinical outcomes. Two of these are estrogen* Correspondence: t.toyama@med.nagoya-cu.ac.jp
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unless otherwise stated.receptor (ER)-positive (luminal A and luminal B) and
three are ER-negative (basal-like, HER2 positive, normal
breast-like) [1,2].
Blenkiron and colleagues analyzed microRNA (miRNA)
expression in human breast cancer, and reported that
many miRNAs were differentially expressed between
breast cancer subtypes including luminal A and luminal B.
They also reported an association between miRNA ex-
pression profiling and clinicopathological factors such as
ERα status and tumor grade [3]. miRNAs are a class of
naturally occurring small non-coding RNAs that control
gene expression by targeting mRNAs for translationalhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Endo et al. BMC Cancer 2014, 14:990 Page 2 of 9
http://www.biomedcentral.com/1471-2407/14/990repression or cleavage [4]. Mature miRNAs recognize sites
in the 3′-untranslated regions (UTR) of the target mRNAs
and cause mRNA degradation or translational repression.
miRNAs have been characterized as oncogenic, tumor
suppressors or as components of regulatory pathways crit-
ical for tumorigenesis [4,5].
In our previous study, we reported a miRNA, miR-1290,
potentially differentiating between luminal A and luminal
B/HER2-negative tumors. We compared expression pro-
files of miRNAs and mRNAs from ERhigh Ki67low and
ERlow Ki67high tumors, which are considered typically
luminal A and luminal B/HER2-negative, respectively. We
also found 4 potential target genes (FOXA1, arylamine
N-acetyltransferase 1 (NAT1), BCL2 and MAPT) of miR-
1290 [6]. Transfection experiments revealed that transfec-
tion of ER-positive breast cancer cells with miRNA-1290
resulted in decreased expression of NAT1 and FOXA1
mRNA but not the other two potential target genes.
Moreover, Western blot analysis showed that miR-1290
induced a dose-dependent decrease in NAT1 protein
expression. Of these potential target genes, NAT1 is the
most promising target of miR-1290 [6].
Arylamine N-acetyltransferases (NATs) are present in
many species. NATs are cytosolic conjugating enzymes
which transfer an acetyl group from acetylCoenzyme A to
a xenobiotic acceptor substrate. Human NATs were origin-
ally identified as drug-metabolizing enzymes [7-9]. Recent
studies focused on their role in the activation and detoxifi-
cation of environmental carcinogens and implicated hu-
man NATs in cancer and in development [7,8,10,11]. The
human NAT gene products NAT1 and NAT2 have distinct
substrate specificities: NAT2 acetylates hydralazine and
NAT1 acetyates p-aminosalicylate (p-AS) and the folate ca-
tabolite p-aminobenzoylglutamate (p-abaglu). Human
NAT2 is mainly present in liver and gut, whereas human
NAT1 and its murine homologue are present in many
adult tissues and in early embryos [12]. NAT1 is one of
the most highly overexpressed genes in ER-positive
relative to ER-negative breast tumors [1,12,13]. More-
over, NAT1 is one of a cluster of genes including the
highly expressed ER in luminal A tumors [2].
The aim of the present study was to clarify whether
NAT1 is a bona fide target of miR-1290 and to investigate
the impact of NAT1 expression on breast cancer prognosis.
Methods
Cell culture and transfections
COS-7 cells (American Type Culture Collection;
ATCC) were grown in RPMI 1640 containing 10% fetal
bovine serum (FBS), 2 mmol/L L-glutamine and
penicillin-streptomycin (50 IU/mL and 50 mg/mL, re-
spectively), at 37°C with 5% CO2. Transfections of pre-
miR-1290 precursor (hsa-miR-1290; Ambion Inc., Austin,
USA) were performed with Cell Line Nucleofector kits(Amaxa Biosystems, Cologne, Germany) using a Nucleofec-
tor device (Amaxa Biosystems) according to the manufac-
turer’s instructions [14]. A nonspecific control miRNA
(Pre-miR miRNA Negative Control #2; Ambion Inc.) was
used as a negative control.
Dual-luciferase reporter assay
The region of human NAT1-3′UTR (bases 52478 to
53073) containing two putative miR-1290-binding sites,
was amplified from MCF7 cells using the PCR primers
listed in Additional file 1: Table S1, and cloned into the
pMIR-report™ luciferase plasmid (Ambion, Austin TX);
these were designated NAT1-wt. Three derivative con-
structs of NAT1-wt with mutations in the putative miR-
1290-binding sites were generated using a QuikChange II
XL Site-Directed Mutagenesis Kit (Agilent Technologies)
and the primers listed in Additional file 1: Table S1, and
were designated NAT1-mut1, −mut2, and -mut1 + 2. All
of the constructs were verified by direct sequencing.
Pre-miR-1290 precursor and a nonspecific control miRNA
were co-transfected with 3 μg each of the reporter vector
constructs and an internal control vector (pGL4.74,
Promega) into COS-7 cells (1 × 106 cells) in a 24-well
format. Luciferase activity was measured 24 hours later
using a dual-luciferase reporter assay system (Promega)
and a Lumat LB9507 luminometer (Berthold Technologies,
Germany). The firefly luciferase activities of the reporter
constructs were normalized against the renilla luciferase
activities of the internal control vector. The degree of
reduction of luciferase activity relative to the samples
transfected with nonspecific control miRNA was taken
as an index of the effect of the miR-1290 on the post-
transcriptional regulation of the NAT1 gene.
Patients and breast cancer tissue
Breast tumor specimens from 394 female patients with
invasive breast carcinoma who were treated at Nagoya
City University Hospital between 1995 and 2009 were
included in the study (Table 1). This protocol was ap-
proved by the Institutional Review Board of Nagoya City
University Graduate School of Medical Sciences and
conformed to the guidelines of the 1996 Declaration of
Helsinki. Written informed consent for the use of the
surgically-resected tumor tissues was provided by all pa-
tients prior to treatment. The samples were chosen from
a continuous series of invasive carcinomas. All patients
underwent surgical treatment (mastectomy or lumpec-
tomy). Patients received appropriate adjuvant endocrine
or chemotherapy for metastatic disease (Table 1).
Immunohistochemistry (IHC)
Tissue microarrays were constructed using paraffin-
embedded, formalin-fixed tissue from 394 breast cancer
samples. Tissue array sections were immunostained with
Table 1 Clinicopathological characteristics of patients
Total
No. of patients 394
Age (years)
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Autostainer (Leica Microsystems, Newcastle, UK) and the
associated Bond Refine Polymer Detection kit [15]. Primary
antibodies included mouse monoclonal anti-human ERα
antibody (1D5, Dako, Glostrup, Denmark) at 1:100 dilu-
tion, mouse monoclonal anti-human PgR antibody (636,
Dako) at 1:100 dilution and rabbit polyclonal anti-humanNAT1 antibody (ab92785, Abcam) at 1:100 dilution. The
expression of ERα and PgR was scored by assigning
proportion and intensity scores, according to Allred’s
procedure [16]. In brief, a proportion score represented
the number of tumor cells staining positive as follows:
0 (none), 1 (<1/100), 2 (1/100 to 1/10), 3 (1/10 to 1/3),
4 (1/3 to 2/3), and 5 (>2/3). Any brown nuclear staining
in the breast epithelium was counted towards the pro-
portion score. An intensity score represented the average
intensity of the positive cells as follows: 0 (none), 1 (weak),
2 (intermediate), 3 (strong). The proportion and intensity
scores were then added to obtain a total score ranging
from 0 to 8. Staining status by IHC was then assessed as
negative (scores 0, 2) or positive (scores 3–8) [17]. Immu-
nostaining of HER2 was evaluated using the HercepTest
(Dako). To determine the level of HER2 expression, the
membrane staining pattern was estimated and scored
on a scale of 0 to 3+. Tumors with a score of 2+ were
tested for gene amplification by fluorescence in situ
hybridization (FISH) using the PathVysion assay (Vysis,
Abbott Laboratories, Abbott Park, IL). A ratio ≥2.0 for
HER2 gene/chromosome 17 was considered positive.
Tumors were considered HER2-positive if IHC staining
was 3+ or they were FISH-positive [18]. NAT1 expres-
sion level was assessed as the percentage of stained
tumor cells (Additional file 2: Figure S1). Tumors with
at least one NAT1-positive tumor cell were considered to
indicate the presence of this protein. The cutoff points for
the expression levels of NAT1 were set at least one stained
cell, which allowed us to obtain the most significant differ-
ence between patient groups in prognostic analyses.
Statistical analysis
Results are expressed as the mean ± S.E. Student’s t test
was used to compare data between two groups. P values
less than 0.05 were considered to be statistically significant.
Estimation of disease-free survival and overall survival was
performed using the Kaplan-Meier method, and differ-
ences between survival curves were assessed with the
Wilcoxon test. Cox’s proportional hazards model was used
for univariate and multivariate analyses of prognostic
values. JMP SAS software (SAS Institute Japan) was used
for data analysis.
Results
Mir-1290 targets the NAT1 3′-UTR directly
Two sites in the NAT1 3′-UTR were predicted to be po-
tential target sites of miR-1290 according to miRanda
(http://www.microrna.org/). To determine whether NAT1
is a direct target of miR-1290, we cloned its 3′-UTR into a
pMIR-report™ luciferase plasmid to perform a reporter
assay (Figure 1A). When miR-1290 precursor was trans-
fected into the cells together with this reporter construct,
luciferase activity was repressed relative to the nonspecific
Luciferase
SV40
Site 1 Site 2
SV 40 Poly A signal
NAT1 -3’UTRSite 1
miR-1290 3’- agGGACUAGG----UUUUUAGGu  -5’
| | | || : : : | | | | | ||
NAT1-wt 3’- ACCTT ATTTTGAAGA AAATCCTAGA䞉䞉
NAT1-mut1 3’- ACCTT ATTTTGAAGA GACGCGTAGA䞉䞉
Site 2
miR-1290 3’- agGGACUAGGUUUUUAGGu  -5’
: | | | | : : : | | | || |
NAT1-wt 3’- A TC TGAG TT GAA A TC CTGT䞉䞉











































Figure 1 Identification of miR-1290 target sites in the NAT1 3′-UTR. A, Schematic of the 3′-UTR-containing reporter constructs for potential
miR-1290 target sites in NAT1. The 3′-UTR of the NAT1 gene was inserted just downstream of the firefly luciferase gene in the pMIR-report
luciferase plasmid (NAT1-wt). Next, the mutated derivatives (Nat1-mut1, −mut2 and –mut1 + 2) of NAT1-wt were generated by inserting mutations into
two putative binding sites corresponding to the seed-sequence of miR-1290. B-E, Cells were transfected with either miR-1290 or nonspecific control
miRNA (NC). Luciferase activity was assayed 24 hr later. The data are shown as luciferase activity relative to the vehicle (pGL4.74).
Endo et al. BMC Cancer 2014, 14:990 Page 4 of 9
http://www.biomedcentral.com/1471-2407/14/990control miRNA (Figure 1B). Furthermore, we cloned each
putative miR-1290-target site having multiple mutants in
their sequences (Figure 1A) that corresponded to the
“seed sequence” of miR-1290 into the pMIR-report
plasmid and performed reporter assays (Figure 1C-E).
When miR-1290 precursor was transfected into cells
with the NAT1-mut1, luciferase activity was still repressed
(Figure 1C), whereas this was no longer the case for
NAT1-mut2 or –mut1 + 2 (Figure 1D, E). These results
suggest that site 2 in the NAT1 3′-UTR is the putative
target site of miR-1290.
Expression of NAT1 protein and its relationship with
clinicopathological factors
The expression levels of NAT1 protein in breast cancer
tissues was examined by immunohistochemistry (IHC).
Levels of NAT1 were positively correlated with ERα
(P < 0.0001) and PgR (P < 0.0001), but negatively corre-
lated with tumor grade and size (P < 0.0001) (Table 2).
The presence of NAT1 is correlated with improved overall
survival
We next analyzed the correlation between the presence
of NAT1 protein in breast cancer tissues and patientprognosis. Kaplan-Meier analysis of all 394 patients to-
gether showed that the presence of NAT1 was not
strongly associated with disease-free or overall survival
(OS), although the latter did show marginal significance
(P = 0.0416) (Figure 2B). We then investigated the correl-
ation between the presence of NAT1 and prognosis in
ERα-positive patients (n = 363). We found no association
between the presence of NAT1 and favorable disease-free
survival (DFS) (P = 0.3461) and OS (P = 0.1319) (data not
shown). However, Kaplan-Meier analysis showed that the
presence of NAT1 was significantly associated with favor-
able DFS (P = 0.0048) and OS (P = 0.0055) in patients
who received adjuvant endocrine therapy with tamoxifen
(n = 176) (Figure 3A and B).
NAT1 protein expression is prognostic for lymph
node-positive breast cancer
We then analyzed NAT1 in tumors from lymph node-
negative (n = 247) and lymph node-positive patients
(n = 147). Kaplan-Meier analysis showed that the pres-
ence of NAT1 was significantly associated with favorable
DFS (P = 0.0025) and OS (P = 0.0007) in lymph node-
positive (Figure 4A and B), but not -negative patients
(Additional file 3: Figure S2). Univariate analysis revealed
Table 2 Correlation between expression levels of NAT1















NAT1 a+ 0.286 + 0.356 -
0.095
- 0.405** - 0.247 - 0.031
b< 0.0001* <0.0001* 0.113 <0.0001* <0.0001* 0.573
aSpeaman’s correlation coefficient.
bP, speaman’s rank correlation test.
*P < 0.05 is considered significant.
**spearman’s correlation coefficient greater than +0.40 or less than −0.40 have
strongly correlate.
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ERα (P = 0.0393), the levels of expression of NAT1
(P = 0.0005), tumor size (P = 0.0028), number of positive
lymph nodes (P = 0.0006) and DFS. Furthermore, NAT1
(P = 0.019) and the number of positive lymph nodes
(P = 0.0122) remained significant when assessed by
multivariate analysis (Table 3). Univariate analysis in-
dicated significant associations between levels of ERα
(P = 0.0034), PgR (P = 0.0221), NAT1 (P = 0.0054),
tumor size (P = 0.0188), number of positive lymph
nodes (P = 0.0048) and OS. In multivariate analysis,
only NAT1 tended to associate with favorable OS but
this was not significant (P = 0.0925) (Table 4).Discussion
We focused on microRNAs and on two different subtypes
of ER-positive breast cancer, and found that miR-1290 and
its potential target NAT1 may be informative for patient
survival. We demonstrated that miR-1290 directly down-





Figure 2 Kaplan-Meier survival analyses of the 394 breast cancer pati
cancer patients stratified according to the presence or absence of NAT1 prbreast cancer patients with tumors expressing NAT1
tended to have better overall survival than those whose
tumors were NAT1-negative. Furthermore, in lymph
node-positive patients, the presence of NAT1 was sig-
nificantly associated with favorable DFS and OS.
Although there are two predicted miR-1290 target
sites in the NAT1 3′-UTR, we found that only site 2 was
the likely target site. The role of miR-1290 has not yet
been analyzed, but it was reported as one of the differen-
tially expressed miRNAs in various cancers, although
not in breast cancer [19,20]. Wu and colleagues reported
that miR-1290 was significantly up-regulated in colon
cancer tissues and that its up-regulation postponed cyto-
kinesis and led to the formation of multinucleated cells.
Moreover, they reported that the enforced expression of
miR-1290 activated the Wnt pathway and increased the
levels of reprogramming-related transcription factors
c-Myc and Nanog [21]. Recently, Li and colleagues re-
ported that serum miR-1290 levels distinguished patients
with low-stage pancreatic cancer from healthy controls
[22]. In a previous study, miR-1290 expression was
strongly down-regulated in luminal A tumors and was
positively correlated with tumor grade.
NATs are polymorphic drug-metabolizing enzymes [12].
There are two closely related genes on chromosome 8 that
encode the two human NATs – NAT1 and NAT2 [7]. Hu-
man NAT1 and its murine homologue are present in
many adult tissues including breast tissue, as well as in
early embryos. Human NAT1 acetylates p-AS and the fol-
ate catabolite p-ABG [8,12], and may contribute to folate
and acetylCoA homeostasis. NAT1 is represented on most
microarray chips, so interrogation of public databases has
revealed changes in NAT1 mRNA levels associated with
different cancers and cancer subtypes [7]. Regarding breast
cancer, several independent studies showed that NAT1
expression clustered with expression of the estrogen recep-














Figure 3 Kaplan-Meier survival analyses of the patients who received adjuvant endocrine therapy with Tamoxifen. Disease-free survival
(A) and overall survival (B) of the 176 patients who received adjuvant endocrine therapy with tamoxifen stratified according to expression of NAT1.
Endo et al. BMC Cancer 2014, 14:990 Page 6 of 9
http://www.biomedcentral.com/1471-2407/14/990receptor was strengthened by Adam et al. who showed by
immunohistochemistry that NAT1 protein levels were
higher in estrogen receptor-positive than negative breast
cancer tissue [23]. In agreement with these data, in the
present study, we showed that expression of NAT1 was
positively correlated with ERα (P < 0.0001).
We showed that NAT1 protein expression was a prog-
nostic marker in breast cancer patients, which supports
previous reports by other groups. High expression of
NAT1 has been shown to correlate with better outcome
among ER-positive breast cancers [24,25]. Furthermore,
in a study of primary male breast cancers, NAT1 positiv-
ity was reported to be correlated with better outcome
[26]. Bieche and colleagues reported a positive correl-
ation between NAT1 mRNA levels and ERα mRNA
levels [24]. One of the reasons for the association be-
tween NAT1 and good prognosis might be the role of
NAT1 as a drug metabolizing enzyme. Bieche and col-





Figure 4 Kaplan-Meier survival analyses of the lymph node-positive b
(B) of the 147 lymph node-positive breast cancer patients stratified accordtamoxifen in ER-positive breast cancer [24] and hypothe-
sized that strong intratumoral NAT1 expression could
lead to increased detoxification of genotoxic and/or estro-
genic tamoxifen metabolites. In addition, Kim and col-
leagues reported that the NAT1 methylation rate was
lower in a control group than in a tamoxifen-resistant
group, and that the expression of NAT1 mRNA was lower
in the latter [27]. Therefore, it seems that NAT1 has an
important role in the response to tamoxifen. In the
present study, we also showed that NAT1 was significantly
associated with favorable DFS and OS in patients who
received adjuvant endocrine therapy with tamoxifen.
Moreover, we showed that patients whose tumors were
NAT1-positive had a significantly more favorable progno-
sis in node-positive breast cancer patients. Almost all pa-
tients (97.3%, 143/147) with metastatic invaded lymph
nodes received adjuvant systemic therapy, not only with
tamoxifen but also other hormonal- and chemo-therap-





reast cancer patients. Disease-free survival (A) and overall survival
ing to expression of NAT1.
Table 3 Univariate and multivariate analysis of factors predicting disease free survival (LN+, n = 147)
Univariate Multivariate
RR 95% CI P RR 95% CI P
ER (Allred score) 0.881 0.789-0.949 0.0393* 0.915 0.817-1.034 0.1491
PgR (Allred score) 0.927 0.839-1.027 0.1456
HER2 1.174 0.684-1.849 0.5326
NAT1 (%) 0.967 0.940-0.987 0.0005* 0.974 0.946-0.996 0.019*
Tumor grade 1.24 0.810-1.936 0.3255
Tumor size 1.367 1.120-1.645 0.0028* 1.048 0.822-1.319 0.698
No. of positive lymph nodes 1.092 1.042-1.137 0.0006* 1.076 1.017-1.131 0.0122*
Cl, cofidence interval. *P < 0.05.
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systemic therapy is considered to be more important in
node-positive than in node-negative patients. NAT1
might influence not only the metabolism of tamoxifen
but also other drugs. We also showed that expression
of NAT1 correlated positively with expression of ERα,
which might be another reason for the correlation
between the presence of NAT1 and good prognosis.
In contrast, NAT1 overexpression can lead to resistance
to certain drugs. Using nontransformed breast epithelial
HB4a cells, Adam and colleagues reported that NAT1
overexpression conferred a growth and survival advantage,
even in low serum concentrations [23]. Moreover, these
cells were more resistant to etoposide-induced cell death,
prompting the authors to suggest that NAT1 may have in-
direct oncogenic effects. Similarly, NAT1 expression was
higher in gemcitabine-resistant Calu3 cells than in sensi-
tive cells. Although we used different drugs, our results
are in contrast to some previous hypotheses. This is a
limitation of this study.
In addition, there have been some reports that NAT1
has an important role in cancer cell biology. The small
molecule inhibitor Rhod-o-hp was used to investigate
the effect of NAT1 inhibition in MDA-MB-231 breast
cancer cells. This resulted in changes in cell proliferation
rates and invasiveness [28]. Moreover, knockdown of
NAT1 expression using short-hairpin RNA (shRNA) inTable 4 Univariate and multivariate analysis of factors predic
Univariate
RR 95% CI
ER (Allred score) 0.804 0.704-0.927
PgR (Allred score) 0.858 0.753-0.978
HER2 1.21 0.569-2.234
NAT1 (%) 0.961 0.914-0.990
Tumor grade 1.655 0.911-3.211
Tumor size 1.372 1.058-1.729
No. of positive lymph nodes 1.097 1.032-1.156
Cl, cofidence interval. *P < 0.05.the noninvasive HT-29 colon cancer cell line resulted in a
marked change in cell morphology that was accompanied
by an increase in cell-cell contact inhibition of growth and
a loss of cell viability at confluence [29]. These reports
pointed to NAT1 as a novel target for anticancer drug de-
velopment. NAT1 might play a role as a predictive factor
for therapeutic effects and act as a therapeutic target,
similar to the ER.
Conclusions
This study demonstrated that miR-1290 directly targets
the NAT1 3′-UTR. We showed that levels of expression
of NAT1 were positively correlated with ERα and PgR,
but negatively correlated with tumor grade and size.
Kaplan-Meier analysis showed that the presence of
NAT1 was significantly associated with increased OS in
breast cancer patients and with DFS and OS in patients
who received adjuvant endocrine therapy with tamoxi-
fen. Moreover, NAT1 was more significantly associated
with increased DFS and OS in lymph node-positive
breast cancer patients. Univariate and multivariate ana-
lyses showed significant associations between levels of
NAT1 and DFS. We conclude that NAT1 might be a suit-
able DFS prognostic biomarker, particularly for lymph
node-positive breast cancer. Thus, miR-1290 and its
potential target NAT1 are associated with characteristics
of breast cancer.ting overall survival (LN+, n = 147)
Multivariate
P RR 95% CI P
0.0034* 0.834 0.704-0.985 0.0324*
0.0221* 0.989 0.845-1.165 0.8875
0.5865
0.0054* 0.973 0.925-1.005 0.0925
0.0998
0.0188* 1.045 0.772-1.381 0.7656
0.0048* 1.09 1.014-1.165 0.0208*
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Additional file 1: Table S1. Primer sequences for generating luciferase
reporter constructs.
Additional file 2: Figure S1. NAT1 immunohistochemical staining of
the breast cancer tissues. A, NAT1 expression level was assessed as 0
percent of positively stained tumor cells. B, NAT1 expression level was
assessed as 12%. C, NAT1 expression level was assessed as 50%. D, NAT1
expression level was assessed as 75%. x400.
Additional file 3: Figure S2. Kaplan-Meier survival analyses of the
lymph node negative breast cancer patients. Disease free survival
(A) and overall survival (B) of the 161 lymph node positive breast cancer
patients stratified according to the presence or absence of NAT1 protein.
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